In early rheumatoid arthritis, comorbidities do not explain the increased risk of failure to reach remission in patients with obesity.

ABSTRACT:

Objective

To examine whether obesity and/or overweight are independently associated with an increased risk of remission failure in patients with early rheumatoid arthritis (RA), treated with methotrexate as first disease-modifying antirheumatic drug, or if the previously reported associations could be explained by underlying comorbidities and lifestyle factors.

Methods

For patients included in the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study 2006-2018 initiating methotrexate monotherapy (n=1285), we captured data on body mass index, comorbidities and disease activity from EIRA and through linkage to nationwide Swedish clinical and quality registers. The primary outcome was failure to reach 28-joint Disease Activity Score (DAS28) remission at 3 and 6 mon

SUBMITTER: Tidblad L 

PROVIDER: S-EPMC12001363 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature